Search
63 studies match these filters. Showing 51–63 of 63 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 832 sites in total · contact listed | Recruiting | Phase 3 | 1,670target | 832 / 4 | 2021 | Apr 23, 2026 | |
| NCT06880055 | Shield Post-Approval Study Protocol The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi… ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 69 sites in total | Recruiting | 3,375target | 69 / 1 | 2025 | Aug 7, 2026 | ||
| NCT06319820 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 193 sites in total | Recruiting | Phase 3 | 641target | 193 / 20 | 2024 | Aug 28, 2026 | |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the g… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 783 sites in total | Recruiting | Phase 2 | 124target | 783 / 1 | 2015 | Sep 2, 2026 | |
| NCT06122077 | Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 36 sites in total · contact listed | Recruiting | 20,000target | 36 / 1 | 2023 | Aug 5, 2025 | ||
| NCT06567743 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 80 sites in total · contact listed | Recruiting | Phase 2 | 325target | 80 / 2 | 2024 | Sep 3, 2026 | |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 181target | 31 / 14 | 2026 | Jun 23, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 | |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 71target | 38 / 16 | 2022 | Jun 15, 2026 | |
| NCT07296484 | Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 61 sites in total · contact listed | Recruiting | Phase 2 | 1,500target | 61 / 1 | 2025 | Sep 9, 2026 | |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyoma… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 120 sites in total | Recruiting | Phase 3 | 1,000target | 120 / 1 | 2023 | Aug 6, 2025 | |
| NCT05336240 | PCOM2 - The Physician Communication Intervention, Version 2.0 Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, wa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 2 sites in total · contact listed | Recruiting | Not applicable | 120target | 2 / 1 | 2023 | Aug 26, 2024 | |
| NCT07546929 | HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 25 sites in total · contact listed | Recruiting | Phase 2 | 300target | 25 / 1 | 2023 | Apr 23, 2026 |